Natarajan Sethuraman sold $339k of TRDA
President, Research & Develop. at Entrada Therapeutics, Inc.. 18,219 shares at an average of $18.62, traded Nov 4, 2024, filed Nov 6, 2024.
Score components
- +20RolePresident
- +15Trade size$339k at market
- 0Share of holdings soldSold 9.9% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +15.7%, 3m -25.0%, 6m -56.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001689375-24-000064, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2024 | SOpen-market sale Common Stock10b5-1 | -749 | $18.02 | $13k | 182,467 | Nov 6, 2024 |
| Nov 5, 2024 | SOpen-market sale Common Stock10b5-1 | -5,171 | $18.18 | $94k | 177,296 | Nov 6, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stock10b5-1 | -9,554 | $18.71 | $179k | 167,742 | Nov 6, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stock10b5-1 | -2,745 | $19.32 | $53k | 164,997 | Nov 6, 2024 |
Related signals
Other insiders at Entrada Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $1.9M 259,837 shares | -6% | |
| 45Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $1.9M 259,837 shares | -6% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $616k 86,914 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $616k 86,914 shares | -2% | |
| 37Weak | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $462k 62,714 shares | -1% | |
| 37Weak | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $462k 62,714 shares | -1% | |
| 37Weak | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $432k 62,811 shares | -2% | |
| 48Moderate | Entrada Therapeutics, Inc. | Kush Parmar director | $1.1M 155,255 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.